MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
24.31
-0.87
-3.44%
Opening 12:20 09/10 EDT
OPEN
24.76
PREV CLOSE
25.18
HIGH
24.89
LOW
23.98
VOLUME
879.89K
TURNOVER
--
52 WEEK HIGH
38.26
52 WEEK LOW
19.36
MARKET CAP
2.51B
P/E (TTM)
-29.8392
1D
5D
1M
3M
1Y
5Y
1D
Cathie Wood Sells $28.6M of Google Stock and Buys $26.4 M of Meta Shares. What Else Is She Buying? September 10
TipRanks · 4h ago
Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today
TipRanks · 16h ago
Wedbush Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
TipRanks · 1d ago
Beam Therapeutics Price Target Maintained With a $65.00/Share by Wedbush
Dow Jones · 1d ago
JonesTrading Remains a Buy on Beam Therapeutics (BEAM)
TipRanks · 1d ago
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Benzinga · 1d ago
Canaccord Genuity Keeps Their Buy Rating on Beam Therapeutics (BEAM)
TipRanks · 1d ago
Beam Therapeutics (BEAM) Gets a Buy from Clear Street
TipRanks · 1d ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.